ATXN3 and Spinocerebellar ataxia type 3: In addition and departing from a cell-based screen for compounds that reduced ATXN3 abundance, Costa et al. (2016) found aripiprazole as a hit compound, showing beneficial effects in vitro using recombinant proteins and in vivo using Drosophila and mouse MJD models, by decreasing ATXN3 levels [10].